Navigation Links
Results From Phase 3 EQUATE Trial of VIVUS' Qnexa Highlighted at European Congress on Obesity
Date:5/7/2009

ing patients who have struggled unsuccessfully to lose weight for years."

The proportion of Qnexa patients losing 5 percent or more of their initial body weight was 66 percent for full-dose, 62 percent for mid-dose and 15 percent for placebo. The proportion of Qnexa patients losing 10 percent or more of their initial body weight was 41 percent for full-dose, 39 percent for mid-dose and 7 percent for placebo.

Qnexa was well-tolerated, with no drug-related serious adverse events in the study. The most common adverse events reported for the full-dose, mid-dose and placebo group were tingling (23%, 16%, 3%), dry mouth (18%, 13%, 0%), headache (16%, 15%, 13%), and constipation (15%, 7%, 8%). The completion rate for the study overall was 70 percent.

"The weight loss seen across our phase 2 and phase 3 obesity and diabetes Qnexa trials to date, coupled with the positive impact observed on other cardiometabolic factors such as blood pressure, cholesterol and glucose, is impressive and potentially represents a step forward in the treatment of obesity and obesity-related conditions," commented Leland Wilson, president and chief executive officer of VIVUS. "We are delighted to see these data - the first of our three phase 3 clinical trials evaluating Qnexa for obesity - highlighted at ECO."

In addition to EQUATE, the phase 3 Qnexa program includes two double-blind, placebo-controlled, multi-center studies that will compare Qnexa to placebo during a 56-week treatment period. The first year-long study, known as EQUIP (OB-302), enrolled morbidly obese patients with a Body Mass Index (BMI) of 35 or greater. The second year-long trial, known as CONQUER (OB-303), enrolled overweight and obese adult patients with BMIs from 27 to 45 and at least two co-morbid conditions, such as hypertension, dyslipidemia and type 2 diabetes. The co-primary endpoints for these studies are the mean percent weight loss and the per
'/>"/>

SOURCE VIVUS, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Boston Scientific Welcomes Publication of HORIZONS AMI Trial Results in New England Journal of Medicine
2. Poniard Pharmaceuticals Reports First Quarter 2009 Financial Results and Provides a Corporate Update
3. Transcept Pharmaceuticals to Report First Quarter 2009 Results
4. Perceptive Informatics Survey Results Reveal Top Barriers to Implementing Adaptive Trial Designs
5. Pharmaxis Announces Positive Results of Phase 3 Cystic Fibrosis Trial
6. Fovea Reports Positive Results with Prednisporin(TM) in Persistent Allergic Conjunctivitis
7. Study Results Present Paradigm Shift; REDUCE Trial Shows New Hope for the Risk Reduction of Prostate Cancer
8. Stallergenes S.A.: Positive Results From a Phase IIb/III Clinical Trial on the House Dust Mite Desensitization Tablet
9. Merz Pharmaceuticals Announces Results of Three Clinical Trials With NT-201 (Botulinum Neurotoxin Type A Free From Complexing Proteins) in Movement Disorder Patients
10. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 First Quarter Results
11. Human Genome Sciences Reports Positive Late-Breaker Results at EASL from ACHIEVE Phase 3 Trials of Albuferon(R) in Patients with Chronic Hepatitis C
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... MEDITE Group acquired by CytoCore, Inc. (OTCBB: CYOE) ... rd quarter sales ended September 30, 2014 of $8.7 ... nine months ended September 2014 and a $38,000 loss for ... quarter is usually a seasonable weak period due to ... for many countries worldwide, we are proud to announce record ...
(Date:11/22/2014)... CHAPEL HILL, N.C. , Nov. 21, 2014 ... the healthcare system. Undoubtedly, the growing influence of ... and spend for marketing interactions. Now, more than ... and retain patients for medical products is essential. ... benchmarking firm, Best Practices, LLC, benchmarked companies spent ...
(Date:11/21/2014)... VIENNA, Va. , Nov. 21, 2014 /PRNewswire/ ... operates in Southern California , today ... caregiving technology. Alta will be providing the innovative BeClose ... services. Logo - http://photos.prnewswire.com/prnh/20141121/160143LOGO ... to providing the kind of affordable 24/7 care our ...
Breaking Medicine Technology:CytoCore Inc. / MEDITE Cancer Diagnostics, Inc. Reports Record YTD and 3rd Quarter Sales 2CytoCore Inc. / MEDITE Cancer Diagnostics, Inc. Reports Record YTD and 3rd Quarter Sales 3New Report Details Importance of Adopting a "Patient Journey" Framework in Marketing 2Alta Home Care, Inc. and BeClose Partner to Enable Seniors to Remain in Their Homes Safely and Securely 2
... INDIANAPOLIS, Dec. 9, 2011   Lilly for Better Health ™, ... ) that helps individuals live healthier, more active lives, has ... The newly enhanced En Espanol section ... practical tips on healthy eating, physical activity and managing health ...
... 2011 NHS National Innovation Centre supports ... Sequana Medical announced today the findings of an ... the National Innovation Centre, the NHS organization which supports ... and use of innovations that will benefit the NHS. ...
Cached Medicine Technology:Lilly for Better Health™ Expands Website to Include Spanish Health Information and Interactive Tools 2Lilly for Better Health™ Expands Website to Include Spanish Health Information and Interactive Tools 3NHS National Innovation Centre Estimates Sequana Medical's ALFApump® System Could Save the NHS £50 Million in ascites Care Annually 2
(Date:11/22/2014)... BambooFlooringChina.com is a famous brand in the bamboo flooring ... of bamboo mats ; the new models are offered ... , According to the sales manager of BambooFlooringChina.com, Bamboo is ... renewable resource. Their bamboo mats are 100% made from natural ... natural bamboo with caramel bamboo strips. , “Bamboo ...
(Date:11/22/2014)... 2014 “Due to my knee replacement surgery, ... Gurnee, Ill. “While using the ice grip attachment, I noticed ... there needed to be a safer way to prevent possible ... , The SPIKE BLOCK offers added safety and stability in ... to reduce injuries and damage associated with traditional spiked ice ...
(Date:11/22/2014)... November 22, 2014 Nocturia is ... the complaint that the individual has to wake ... The report “Nocturia – Pipeline Review, H2 2014” ... Nocturia, complete with comparative analysis at various stages, ... (MoA), route of administration (RoA) and molecule type, ...
(Date:11/22/2014)... 22, 2014 Domestic farmgate milk ... in 2009-10, due to a fall in demand ... industry products amid the global financial crisis. However, ... of Australian dairy manufacturers on the international scene. ... outweighed supply growth, primarily due to supply constraints ...
(Date:11/22/2014)... Lipitor lawsuits ( http://www.lipitorlawsuitcenter.com/ ) that ... developed Type 2 diabetes due to its use continue ... underway in U.S. District Court, District of South Carolina, ... litigation will convene its next Status Conference on December ... Counsel for Plaintiffs and Defendants to meet and confer, ...
Breaking Medicine News(10 mins):Health News:Trendy Bamboo Mats Online Now By BambooFlooringChina.com 2Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 2Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 3Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 4Health News:Butter and Dairy Product Manufacturing in Australia Industry Market Research Report Now Updated by IBISWorld 2Health News:Butter and Dairy Product Manufacturing in Australia Industry Market Research Report Now Updated by IBISWorld 3Health News:Butter and Dairy Product Manufacturing in Australia Industry Market Research Report Now Updated by IBISWorld 4Health News:Lipitor Lawsuit Conference Scheduled for December, Bernstein Liebhard LLP Reports 2Health News:Lipitor Lawsuit Conference Scheduled for December, Bernstein Liebhard LLP Reports 3
... ... of cognitive fitness for improved longevity , ... NEW YORK (PRWEB) March 30, 2010 -- CogniFit™, Inc., a leading maker ... in the field of longevity, author and speaker, is now an official spokesperson for CogniFit. ...
... ... on elder care law, released this statement concerning a March/April AARP article entitled "Love is ... married for 44 years was forced to divorce in order to protect their remaining savings ... completely off the mark , ...
... ... EHR/PM solution to area physician practices , ... Dallas, TX (Vocus) March 30, 2010 -- Aprima Medical ... revenue cycle management solutions for medical practices, today announced a value-added reseller agreement with ...
... of the sex hormones, testosterone in men and estrogen ... regenerative potential of cartilage tissue. The study suggests hormone ... might be beneficial in treating late stages of human ... this evidence-based study appear in the April issue of ...
... fatal and others much less severe is largely a ... variability can be attributed to differences in how individuals ... the Society for General Microbiology,s spring meeting in Edinburgh ... tool to allow treatments to be tailored to individuals. ...
... less likely to breast-feed than other women , ... breast-feeding may explain why black American women are less ... new study shows. , About 60 percent of black ... 77 percent of white infants, according to the researchers, ...
Cached Medicine News:Health News:CogniFit and Longevity Expert Cooperate to Raise Awareness for the Benefits of Brain Fitness 2Health News:CogniFit and Longevity Expert Cooperate to Raise Awareness for the Benefits of Brain Fitness 3Health News:Prominent National Elder Law Attorney Disputes AARP Article Recommending Divorce to Afford Health Care 2Health News:Prominent National Elder Law Attorney Disputes AARP Article Recommending Divorce to Afford Health Care 3Health News:Aprima and ProviDyn, Inc. Partner to Provide Electronic Health Records to Georgia Medical Practices 2Health News:Hormone replacement in joint fluid has potential regenerative effect 2Health News:Personalizing medicine to prevent pandemics 2Health News:Black Women in U.S. Comfortable With Formula Feeding 2
Sterile squares of smooth foil for repair of the floor of the orbit and other plastic surgery. Available in large size....
Segment stand magnifiers come complete with bar magnifier to achieve a higher magnification while still maintaining a wide binocular field of view....
The Multi-Purpose Stand Magnifier is the most versatile stand magnifier. The stand has multiple configurations allowing for all situations where hands-free magnification is needed....
Contour design eyelid implants....
Medicine Products: